SEHK:2269Life Sciences
WuXi Biologics Alliances Deepen Role In Complex Autoimmune And Fusion Drugs
WuXi Biologics (Cayman) (SEHK:2269) announced new alliances with Vertex Pharmaceuticals and Sinorda Biomedicine for co-development and manufacturing of biologics targeting autoimmune diseases.
The company also expanded its agreement with HanchorBio to cover next generation fusion protein programs.
Together, these collaborations broaden WuXi Biologics' role as a global contract research, development and manufacturing partner across multiple therapeutic modalities.
WuXi Biologics focuses on...